Form D · Pharmaceuticals

Vitruvias Therapeutics, Inc.

Auburn, AL · CIK 0001592342

Offering snapshot reported Jan 5, 2018 · SEC filing

Reported sold
$11.5M
Offering amount: $11.5M
Investors reported
23
Form D · investor count
Minimum accepted
$25K
Reported outside-investor minimum
First sale
Dec 26, 2017
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported investors0 → 23

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jan 5, 2018Amendment$11,500,000No comparison23SEC filing
Dec 20, 2017InitialYet to sellNo comparison0SEC filing
Jul 30, 2014Amendment$200,000$0vs Jul 29, 20142SEC filing
Jul 29, 2014Initial$200,000No comparison2SEC filing
Nov 19, 2013Initial$750,000No comparison9SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-301275
Sale occurred on December 26, 2017.

Source: Form D, filed Jan 5, 2018. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Michael Altman Director
Roger D Graben Executive
Bryce M Harvey Director, Executive
A Stuart Hendon Director
Thomas A Main Director
Edward Schutter Director
Charles T Smith Director
Carl L Whatley Director, Executive
Carl Leo Whatley, Jr. Executive
Jason Wild Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
670 North College Street Suite B
Auburn, AL, 36830